Home›Cancer›Lymphoma – Description and Treatment Options

The lymphatic system is part of the immune system responsible for eliminating toxins. Lymphoma develops when cells in the lymphatic system become altered and begin to multiply uncontrollably. Although it originates in the lymphatic system, lymphoma can spread through the blood to other parts of the body and cause blood-related symptoms such as anemia, low white blood cell count, bleeding, or bruising.

Lymphoma Symptoms

Lymphoma symptoms can vary widely and depend on the type of lymphoma. The most common lymphoma symptoms are:


• Enlarged lymph nodes
• Abdominal pain
• Elevated body temperature
• Skin rashes
• Weight loss
• Bleeding

Types of Lymphoma

There are several types of lymphoma, which differ in their disease course and treatment approaches. These include:


• Hodgkin lymphoma
• Non-Hodgkin lymphoma

Hodgkin Lymphoma

Hodgkin lymphoma is a rarer form of lymphoma, but it is more treatable than non-Hodgkin lymphoma. It presents as lymph node involvement, and it is very important to start treatment as soon as possible to prevent further spread.

Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma is a more common form of lymphoma and is more difficult to treat than Hodgkin lymphoma. It presents as lymph node involvement and can spread to other organs, so timely initiation of treatment is also especially important.

Lymphoma Treatment

Lymphoma treatment depends on the type and severity of the disease. The most commonly used treatment methods are: • Chemotherapy • Radiotherapy • Adjunctive therapy

Chemotherapy

Chemotherapy is one of the most commonly used treatments for lymphoma. It involves the use of special medications that destroy cancer cells. A course of chemotherapy can last several months and may cause side effects such as fatigue, headache, nausea, and vomiting. How to reduce?

Radiotherapy

Radiotherapy is another common treatment for lymphoma. It involves exposing the cancerous area to radiation to destroy cancer cells. A course of radiotherapy can last several weeks and may cause side effects such as skin redness and itching.

Can I help myself additionally?

You need to balance your diet and other factors that only YOU can control. This will help the immune system function more effectively, and cancer treatment (such as chemotherapy) will be even more effective. With natural immune system modulators (such as Lentinan), you can help your immunity fight cancer cells.

We also recommend performing breathing exercises according to the Wim Hof method and exercising.

What can we do in the fight against lymphoma?

⚛
What can we do in the fight against cancer?

Cancer knows how to send signals that mask itself, making it difficult for the immune system to detect it. Lentinan AXT from Zenius Labs™ – an advanced mushroom polysaccharide formula designed to strengthen the immune system during oncological diseases.

More about Lentinan AXT →

References
  1. Diffuse Large B-Cell Lymphoma. PubMed
  2. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. PubMed
  3. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. PubMed
  4. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and .... PubMed
  5. Evolving molecular classification of aggressive B-cell lymphoma. PubMed
  6. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. PubMed
  7. Tani M et al. In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan. European journal of clinical pharmacology. 1992. PubMed
  8. Hamano K et al. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. International journal of immunopharmacology. 1999. PubMed
  9. Mattiola I et al. The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. Nature immunology. 2019. PubMed
  10. Zhou X et al. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. The oncologist. 2008. PubMed
  11. Li B et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. Journal of immunology (Baltimore, Md. : 1950). 2006. PubMed
  12. Xia Y et al. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. Journal of immunology (Baltimore, Md. : 1950). 1999. PubMed
  13. Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
  14. Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
  15. Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
  16. Adachi Y et al. Potentiation of Antitumor Activity by Antibody Drugs and Mushroom-Derived β-Glucans in Natural Killer Cell-Mediated Tumoricidal Activities against Non-Hodgkin's B-Cell Lymphoma. International journal of medicinal mushrooms. 2023. PubMed
  17. Sam J et al. Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma. Blood. 2025. PubMed
  18. Ansell SM et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England journal of medicine. 2015. PubMed
  19. Azoulay T et al. Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression. Cancer immunology, immunotherapy : CII. 2023. PubMed
  20. Sato A et al. [Pathogenesis and novel therapy for EBV-related B-cell lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2016. PubMed
  21. Chen J et al. Epstein-Barr virus: biology, pathogenesis and therapy of lymphomas. Discover oncology. 2025. PubMed
  22. Liquidano-Perez E et al. Case Report: Hydroa vacciniforme-like lymphoproliferative disorder, an EBV-associated disease, successfully treated with hematopoietic stem cell transplantation. Frontiers in immunology. 2025. PubMed
  23. Song JY et al. Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma. Haematologica. 2023. PubMed
  24. Greenbaum AM et al. Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8(+) T-cells despite immune checkpoint signaling. Blood research. 2022. PubMed
  25. Liu WR et al. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood. 2017. PubMed
  26. Wang D et al. Dectin-1 stimulates IL-33 expression in dendritic cells via upregulation of IRF4. Laboratory investigation; a journal of technical methods and pathology. 2018. PubMed
  27. Engel AL et al. Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. Immunobiology. 2013. PubMed
  28. Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
  29. Oba K et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer research. 2009. PubMed
  30. Wang Y et al. Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis. Medicine. 2024. PubMed
  31. Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
  32. Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
  33. Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
  34. Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
  35. van der Meer JW et al. Trained immunity: A smart way to enhance innate immune defence. Molecular immunology. 2015. PubMed
  36. Vuscan P et al. Potent induction of trained immunity by Saccharomyces cerevisiae β-glucans. Frontiers in immunology. 2024. PubMed
  37. Zou X et al. Radioprotective effect of edible and medicinal mushrooms against ionizing radiation: Components, potential mechanisms, and applications. Food research international (Ottawa, Ont.). 2025. PubMed
  38. Liu F et al. The mechanisms for the radioprotective effect of beta-d-glucan on high linear-energy-transfer carbon ion irradiated mice. International journal of biological macromolecules. 2019. PubMed
  39. Christophersen OA Radiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposure. Microbial ecology in health and disease. 2012. PubMed
  40. Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
  41. Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
  42. Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed

Related articles

Cancer — everything you need to know
Chemotherapy
Breast cancer
Cancer Diet
Lentinan